文献速递类风湿关节炎

类风湿关节炎初始糖皮质激素桥接治疗:是否影响随时间推移的糖皮质激素使用

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
PubMed 文献 · Ann Rheum Dis · 2024-01-02

该研究将BeSt、CareRA和COBRA三项试验的患者个体数据合并进行荟萃分析,比较接受与未接受初始糖皮质激素(GC)桥接治疗的类风湿关节炎(RA)患者随时间推移的GC使用情况。结果显示桥接组早期临床改善更快、改善病情抗风湿药(DMARD)更换次数更少,桥接期除外后两组后期GC使用均低且累积剂量相似,但按方案桥接导致24个月累积GC剂量更高。

要点

  • 桥接组前6个月DAS28改善更快(p<0.001),DMARD更换率显著更低(发生率比0.59,95%CI 0.38至0.94)。
  • 桥接期除外后两组后期GC使用均低且累积剂量相似,但桥接组12个月时GC使用更高(OR 3.27,95%CI 1.06至10.08)。
  • 按方案桥接导致24个月累积GC剂量差异为2406 mg(95%CI 1403至3408)。

核心结论

  • 在比较GC桥接与无GC桥接的随机试验中,桥接组临床改善更迅速、DMARD更换更少,且与非桥接组相比后期GC使用相似。
  • 按方案进行GC桥接如预期导致2年内累积GC剂量更高。

研究设计与样本

  • 将BeSt、CareRA和COBRA三项试验的数据合并进行患者个体数据(IPD)荟萃分析。
  • 625例患者中252例(40%)被随机分配至GC桥接组(桥接组)。
  • 采用混合效应回归分析比较桥接组与非桥接组在基线后12、18和24个月时的GC使用情况。

主要发现

  • 桥接组与非桥接组平均DAS28相似,但桥接组前6个月改善更快(p<0.001)。
  • 桥接组所需DMARD更换显著更少(发生率比0.59,95%CI 0.38至0.94)。
  • 桥接组12个月时GC使用更高(OR 3.27,95%CI 1.06至10.08)。
  • 桥接方案导致24个月累积GC剂量差异为2406 mg(95%CI 1403至3408)。
  • 桥接期除外后,两组后期GC使用均低且累积剂量相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the use of glucocorticoids (GC) over time in patients with rheumatoid arthritis (RA) who were or were not treated initially with GC bridging therapy. METHODS: Data from the BeSt, CareRA and COBRA trials were combined in an individual patient data (IPD) meta-analysis. We compared GC use between bridgers and non-bridgers at 12, 18 and 24 months from baseline with mixed-effects regression analysis. Secondary outcomes were mean cumulative GC dose until 24 months after baseline with and without the bridging period, Disease Activity Score based on 28 joints (DAS28) over time and number of disease-modifying antirheumatic drug (DMARD) changes. RESULTS: 252/625 patients (40%) were randomised to GC bridging (bridgers). Excluding the period of bridging, later GC use was low in both groups and cumulative doses were similar. Mean DAS28 was similar between the groups, but bridgers improved more rapidly (p<0.001) in the first 6 months and the bridgers required significantly fewer changes in DMARDs (incidence rate ratio 0.59 (95% CI 0.38 to 0.94)). GC use was higher in the bridgers at t=12 months (OR 3.27 (95% CI 1.06 to 10.08)) and the bridging schedules resulted in a difference in cumulative GC dose of 2406 mg (95% CI 1403 to 3408) over 24 months. CONCLUSION: In randomised trials comparing GC bridging and no GC bridging, bridgers had a more rapid clinical improvement, fewer DMARD changes and similar late use of GC compared with non-bridgers. GC bridging per protocol resulted, as could be expected, in a higher cumulative GC dose over 2 years.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Ouwerkerk L, Verschueren P, Boers M, et al. Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? Ann Rheum Dis. 2024. PMID: 37607810. doi:10.1136/ard-2023-224270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。